Tempus AI agreed to acquire Personalis for $1.5 billion, adding NeXT Personal — a tumour-informed molecular residual disease blood test — as it pushes its oncology business beyond diagnosis and treatment selection into recurrence monitoring. The deal gives Tempus in-house access to a test already covered by Medicare in three indications; Personalis also reported 10,384 clinical tests in Q2, up 33% sequentially, on preliminary revenue of $22.4 million.

Why It Matters To Oncology

• The acquisition expands Tempus from cancer diagnosis and therapy selection into longitudinal monitoring for residual disease and recurrence.

• NeXT Personal uses whole-genome sequencing to build a patient-specific tumour signature, then tracks matching circulating tumour DNA in blood over time.

• For clinicians, that could support treatment-response assessment, detection of molecular residual disease, and earlier identification of relapse that may not yet appear on imaging.

• The test is already Medicare-covered in three indications, which may ease near-term clinical adoption.

The Financials

• Tempus is offering $16.25 per share, valuing Personalis at $1.5 billion.

• That represents a 6% premium to Personalis' July 17 close.

• The transaction will be settled largely in stock, though Tempus can elect to pay up to half in cash.

• On the announcement, Personalis shares fell more than 13% and Tempus shares dropped nearly 9%.

What They're Saying

• Reuters reported investor skepticism may reflect the stock-heavy structure and uncertainty among Personalis holders about Tempus' upside.

• Tempus CEO Eric Lefkofsky said the company waited until the testing business was closer to stronger gross profit and margin performance before moving to buy it.

• Tempus had already been co-commercializing NeXT Personal since 2023 in lung cancer, breast cancer, and immunotherapy monitoring.

• In 2024, Tempus expanded the relationship and invested about $36 million, lifting its stake in Personalis to roughly 19.3%.

What's Next

• The deal is expected to close in late 2026 or early 2027, pending Personalis shareholder approval and regulatory clearance.

• Clinicians and drug developers will be watching whether Tempus can integrate MRD testing into its broader oncology platform and care pathways.

• A key question is whether broader use of tumour-informed ctDNA monitoring will translate into more actionable recurrence detection and better trial stratification.

• The acquisition also positions Tempus more directly in the fast-growing MRD market as oncology diagnostics shift toward post-treatment surveillance.